Last reviewed · How we verify

NCT05290675

Quantra QPlus Sample Type Comparison

Completed Last updated 1 May 2023
What this trial tests

trial testing Quantra QPlus System in Coagulation Defect; Bleeding in 50 participants. Completed in 2 November 2022.

Timeline
4 November 2021
Primary endpoint
31 August 2022
2 November 2022

Quick facts

Lead sponsorHemoSonics LLC
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date4 November 2021
Primary completion31 August 2022
Estimated completion2 November 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

HemoSonics LLC — full company profile →

Who can join

18 and older, any sex, with Coagulation Defect; Bleeding. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center prospective observational study to compare QPlus parameter measurements in arterial and venous blood samples collected in parallel from patients undergoing cardiac surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Quantra QPlus System

Trials testing the same drug.

Other HemoSonics LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05290675.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing